Replies to post #49413 on Ocata Therapeutics Inc fka OCAT

[ddls]

ACTC is a money trap. You can see that there is no interest in stay-
ing in it from the way it's trading.
Now, it can't get above 9 cents.
The SEC is coming up next, so buyers beware!

Quote from ACT's 10Q-3
"We expect that research and development expenses will increase."
"We have no therapeutic products currently available for sale."
"We continue to repay our debt financing's in shares of common stock."

The 10Q-4 will be interesting to see how much sugar coating they do.
I wonder if it will include:
"We expect that research and development expenses will increase."
"We have no therapeutic products currently available for sale."
"We continue to repay our debt financing's in shares of common stock."

[ddls]

Also,
I would love to accept ACTC as my stock of choice. I realize all the
possible money making potential. But, after reading the last 10Q-3
"real good" I saw this:


"We continue to repay our debt financing's in shares of common stock, enabling us to use our cash resources to fund our operations."

"We have no therapeutic products currently available for sale and do not expect to have any therapeutic products commercially available for sale for a period of years, if at all. These factors indicate that our ability to continue research and development activities is dependent upon the ability of management to obtain additional financing as required."

"We expect that research and development expenses will increase in the foreseeable future as we add personnel, expand our pre-clinical research, continue clinical trial activities, and increase our regulatory compliance capabilities."

Umgawa>?